Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Tirzepatide is a GLP-1 and GIP receptor agonist licensed in the UK for type 2 diabetes mellitus treatment Lightheadedness occurs through reduced fluid intake from gastrointestinal effects, blood pressure lowering from weight loss, or hypoglycaemia when combined with insulin or sulfonylureas Seek immediate medical attention for loss of consciousness, chest pain, severe confusion, or persistent vomiting preventing fluid intake Management includes maintaining adequate hydration (6-8 glasses daily), eating regular small meals, rising gradually from sitting or lying positions, and medication review with your GP Report frequent or concerning lightheadedness to your healthcare team within 24 hours for dose adjustment or investigation of alternative causes Table of Contents Why Mounjaro Can Cause Lightheadedness Mounjaro (tirzepatide) is a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus
-1775582746855.png&w=3840&q=75)
When selecting a treatment regimen, consider factors such as cardiovascular and renal comorbidities, drug efficacy and adverse effects, hypoglycemic risk, presence of overweight or obesity, cost, access, and patient preferences
Common side effects of GLP-1 drugs include nausea, diarrhea, vomiting and dizziness
The British Menopause Society recommends using non-oral progestogen for 4 weeks after starting GLP-1 treatment and for 4 weeks after any dose increase
Archived from the original on 10 April 2017
Bone and cardiovascular health GLP-1RAs influence bone metabolism by promoting bone formation and reducing resorption, potentially mitigating osteoporosis risk
